Market Overview

UPDATE: Leerink Reiterates Outperform on BioMarin on Positive Cancer Drug Test Results

Share:

In a report published on Monday, Leerink analyst Joseph Schwartz reiterated an Outperform rating on BioMarin (NASDAQ: BMRN) and maintained a $70.00 price target on the release of its full Phase 1/2 data on poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors. These treatments showed good responses in BRCA cancer and breast cancer patients.

In the announcement, BioMarin said that drug response rates in patients exceeded the 30 percent threshold, this might be an underestimation because many patients haven't received the maximum tolerated dose.

According to Bloomberg data, BioMarin has 17 Buy ratings and 7 Holds. Prior to Monday, shares of the the stock gained 27 percent YTD. Shares are down about 7.8 percent at the time of publication. BioMarin closed Friday at $62.70.

Latest Ratings for BMRN

DateFirmActionFromTo
Apr 2019MaintainsOutperformOutperform
Apr 2019ReinstatesOutperform
Jan 2019DowngradesMarket OutperformMarket Perform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Joseph Schwartz LeerinkAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XELMaintains60.0
SOMaintains54.0
SREMaintains141.0
EXCMaintains56.0
ESMaintains77.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Expect Further Downside In US Dollar

This Small ETF Dispels False Liquidity Views